Core Viewpoint - Jinchang Investment Co., Ltd. plans to transfer 71.509 million shares of Guangyuyuan (600771) to its controlling shareholder, Shennong Technology Group, which represents 14.61% of the company's total share capital [1][2] Summary by Sections Share Transfer Details - The share transfer price is set at 16.53 yuan per share, resulting in a total transaction amount of 1.182 billion yuan [2] - Following this equity change, the largest shareholder of the company will shift from Jinchang Investment to Shennong Technology Group, while the controlling shareholder remains Shennong Technology Group, and the actual controller continues to be the Shanxi Provincial State-owned Assets Supervision and Administration Commission [2]

广誉远中药股份有限公司 简式权益变动报告书 广誉远中药股份有限公司 简式权益变动报告书 上市公司名称：广誉远中药股份有限公司 股票上市地点：上海证券交易所 股票简称：广誉远 股票代码：600771 信息披露义务人：晋创投资有限公司 住所/通信地址：山西转型综合改革示范区学府产业园智创 城东渠路西二巷6号C座5层 股份变动性质：减少 签署日期：2024年12月 广誉远中药股份有限公司 简式权益变动报告书 声 明 一、本权益变动报告书系信息披露义务人依据《公司法》《证券法》《收 购管理办法》《15号准则》及其他相关法律、法规及部门规章的有关规定编写。 二、依据《证券法》《收购管理办法》及《15号准则》的规定，本报告书 已全面披露信息披露义务人在广誉远中药股份有限公司拥有权益的股份变动情 况。截至本报告书签署日，除本报告书披露的信息外，上述信息披露义务人没 有通过任何其他方式增加或减少其在广誉远中药股份有限公司中拥有权益的股 份。 三、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 四、本次权益变动尚需：1、取得上海证券交易所合规性确认 ...

证券代码：600771 证券简称：广誉远 编号：临2024-042 广誉远中药股份有限公司 关于控股股东权益变动的提示性公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 广誉远中药股份有限公司（以下简称"公司"）控股股东神农科技集团有限公司 （以下简称"神农科技集团"）与晋创投资有限公司（以下简称"晋创投资"）签署了 《晋创投资有限公司与神农科技集团有限公司关于广誉远中药股份有限公司之股份转让协 议》（以下简称"《股份转让协议》"），晋创投资拟以非公开协议转让方式向神农科技 集团转让其持有的公司71,508,968股股份，占公司总股本的14.61%，同时解除此前晋创 投资委托神农科技集团行使的14.61%股份对应表决权委托。 本次权益变动不触及要约收购。本次权益变动后，公司第一大股东由晋创投资变 更为神农科技集团，控股股东仍为神农科技集团，实际控制人仍为山西省人民政府国有 资产监督管理委员会。本次股份转让不涉及公司控制权变更，本次权益变动不会导致公 司控股股东及实际控制人发生变化。 本次股份 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-041 广誉远中药股份有限公司 关于重大诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生负面影响：该案件不会对公司损益产生负面影响。 鉴于本案尚未正式开庭审理，预计不会对公司本期利润产生重大影响，对期后利润的影 响尚无法做出准确预判，最终实际影响以法院生效裁判结果和相应的执行情况为准。 一、本次重大诉讼起诉的基本情况 广誉远中药股份有限公司（以下简称"公司"或"原告"）因业绩承诺补偿引起的 合同纠纷对西安东盛集团有限公司（以下简称"被告"）提起诉讼，陕西省西安市中级 人民法院已登记立案。 截至本公告披露日，陕西省西安市中级人民法院已组织双方进行了证据交换，本次 诉讼尚未正式开庭审理。 本次重大诉讼案件的事实、请求及理由的具体内容详见公司于2024年6月21日披露 的临2024—031号公告。 1 案件所处的诉讼阶段：已组织双方进行了证据交换，尚未正式开庭。 上市公司所处的当事人地位：原告。 涉案的金额：暂定合计 ...

Group 1: Company Overview and Core Products - Guangyuyuan Traditional Chinese Medicine Co., Ltd. has a history of over 500 years, with core products including Gui Ling Ji, Ding Kun Dan, and An Gong Niu Huang Wan, which are recognized for their unique advantages [6][11]. - Gui Ling Ji is referred to as the "living fossil of traditional Chinese medicine," highlighting the company's historical legacy and brand quality [6][11]. Group 2: Market Performance and Financials - In Q3 2024, the company's revenue decreased by 15.52% year-on-year, attributed to a decline in market demand and changes in product policies [8][10]. - The company reported a 7.93% decline in revenue for the first three quarters of 2024, influenced by insufficient market demand and intensified competition [10][8]. Group 3: Marketing and Brand Strategy - The company emphasizes brand building and cultural heritage, focusing on academic promotion and precise targeting of consumer groups [3][4]. - Marketing strategies include collaborations with chain pharmacies, community health services, and educational initiatives to enhance consumer understanding of traditional Chinese medicine [4][3]. Group 4: Product Development and Innovation - The company is committed to continuous research and innovation, actively exploring new channels and ensuring product quality [4][6]. - There is a focus on enhancing the efficacy of products aimed at improving immunity, reproductive health, and liver protection, particularly for middle-aged and elderly populations [2][3]. Group 5: Investor Relations and Corporate Governance - The company maintains open communication with investors, encouraging feedback and suggestions through various platforms [16][18]. - There is a commitment to improving shareholder returns and managing expectations, recognizing shareholders as both owners and consumers of the company [5][10]. Group 6: Future Outlook and Strategic Initiatives - The company plans to leverage national policies to expand its market presence in Southeast Asia, with a focus on enhancing brand influence and market competitiveness [15][14]. - Future strategies include optimizing marketing policies, enhancing service quality, and improving operational efficiency to drive sustainable growth [10][17].

证券代码：600771 证券简称：广誉远 编号：临 2024-040 广誉远中药股份有限公司 关于召开 2024 年第三季度业绩说明会的预告公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 25 日（星期一）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络文字互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2024 年 11 月 22 日 15:00 前 访 问 网 址 https://eseb.cn/1jyei1FP42s 或使用微信扫描下方小程序码进行会前提问，公司将 通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回 答。 （www.ir-online.cn）举办 2024 年第三季度报告业绩说明会，与投资者进行沟通和交 流，广泛听取投资者的意见和建议。 二、说明会召开的时间、地点和方式 会议召开时间：2024 年 11 月 25 日（星期一）15:00-16:00 会议召 ...

广誉远中药股份有限公司舆情管理制度（试行） 第一章 总则 第一条 为了完善广誉远中药股份有限公司（以下简称公司）内部管理制度体系， 提高公司应对各类舆情的规范管理水平和工作效率，建立快速反应和应急处置机制， 及时、妥善处理各类舆情对公司市场形象、商业信誉及正常生产经营活动造成的影响， 切实保护公司及全体投资者合法权益，根据相关法律法规及规范性文件和《公司章程》 等相关规定，结合公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、杂志、电视、广播、网络等媒体、自媒体对公司进行的负面或不实 报道、分析、猜测、恶意抨击等； （二）社会上存在的已经或将给公司形象和信誉造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资判断，造成股价异常波动的未公开信 息或不实信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大影 响的事件信息。 第三条 本制度属于公司具体规章制度，适用于公司总部各部室、各子公司及事 业部。 第二章 舆情管理的组织机构及其工作职责 第四条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第五条 公司成立舆情管理工作领导小组（以下简 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-037 广誉远中药股份有限公司（以下简称"公司"）董事会于近日收到副董事长杨波女士 的书面辞职报告，杨波女士因工作调整原因，辞去公司副董事长、董事及董事会各专门委员 会职务，辞职后，杨波女士不再担任上市公司任何职务。根据《公司章程》的相关规定，其 辞职报告自送达公司董事会之日起生效。 公司及董事会对杨波女士在任职期间为公司发展所做出的贡献表示衷心的感谢！ 特此公告。 广誉远中药股份有限公司董事会 二○二四年十月二十五日 广誉远中药股份有限公司 关于副董事长辞职的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥233,925,588.87, a decrease of 15.52% compared to ¥273,958,024.48 in the same period last year[4] - Net profit attributable to shareholders for Q3 2024 was ¥11,361,158.38, down 70.98% from ¥14,423,083.20 year-on-year[4] - The net profit after deducting non-recurring gains and losses for Q3 2024 was ¥9,488,994.37, a decrease of 64.19% compared to ¥2,675,325.40 in the previous year[4] - The basic earnings per share for Q3 2024 was ¥0.02, down 75.00% from ¥0.03 in the same period last year[4] - Total operating revenue for the first three quarters of 2024 was CNY 893,525,764.69, a decrease of 7.93% compared to CNY 970,470,739.58 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was CNY 80,327,259.54, compared to CNY 93,614,632.03 in 2023, indicating a decline of 14.14%[15] - The total comprehensive income for Q3 2024 was ¥80,327,259.54, down from ¥93,614,632.03 in Q3 2023, reflecting a decline of 14.1%[16] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥136,053,785.23, a decline of 62.16% compared to ¥359,515,911.53 in the same period last year[4] - Cash inflows from operating activities totaled ¥1,197,449,684.17 in the first three quarters of 2024, up from ¥1,150,676,072.65 in the same period of 2023, representing a growth of 4.1%[17] - Cash outflows from operating activities increased to ¥1,061,395,898.94 in Q3 2024, compared to ¥791,160,161.12 in Q3 2023, marking a significant rise of 34.2%[17] - The net cash flow from operating activities for the first three quarters of 2024 was ¥136,053,785.23, down 62.2% from ¥359,515,911.53 in the same period of 2023[17] - Cash and cash equivalents at the end of Q3 2024 were ¥135,999,306.73, a decrease from ¥225,853,031.40 at the end of Q3 2023, reflecting a decline of 39.7%[18] - The company reported a significant decrease in cash flow due to increased raw material prices and timely payments to suppliers[7] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,402,750,926.24, down 8.59% from ¥2,628,413,544.42 at the end of the previous year[5] - Total liabilities decreased to CNY 814,559,959.25 in 2024 from CNY 1,120,549,836.97 in 2023, a reduction of 27.24%[14] - The total equity attributable to shareholders increased to CNY 1,567,091,851.02 in 2024 from CNY 1,496,127,641.31 in 2023, an increase of 4.76%[14] - The company received government subsidies amounting to ¥14,914,371.03 year-to-date, which contributed to the financial results[6] Shareholder Information - As of September 30, 2024, the total number of ordinary shareholders is 65,354, with the largest shareholder, Jinchang Investment Co., Ltd., holding 71,508,968 shares, representing 14.61% of the total share capital[8] - The company has a total of 2,724,500 shares directly held by its controlling shareholder, Shennong Technology Group, which represents 0.56% of the total share capital[11] - The company has not reported any changes in the status of pledged, marked, or frozen shares for the top shareholders[9] - The company’s major shareholders have not disclosed any known relationships or agreements that would classify them as acting in concert under the relevant regulations[9] Inventory and Receivables - Accounts receivable decreased to ¥381,395,050.41 from ¥488,346,960.66, reflecting a reduction of about 22%[12] - Inventory increased significantly to ¥761,541,437.18 from ¥569,530,008.23, marking an increase of approximately 33.7%[12] - The company reported a significant increase in other receivables, rising to ¥72,393,238.37 from ¥8,031,217.93, indicating a growth of over 800%[12] Research and Development - Research and development expenses increased to CNY 27,910,261.53 in 2024 from CNY 24,426,723.77 in 2023, representing a growth of 10.16%[15] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness despite the current financial challenges[15] Future Plans - The company plans to increase its shareholding through market transactions, with a planned investment between ¥50 million and ¥100 million over the next 12 months, starting from August 26, 2024[11]

证券代码：600771 证券简称：广誉远 编号：临 2024-039 4、公司全体监事承诺 2024 年第三季度报告所载资料不存在任何虚假记载、误导性 陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特此公告。 广誉远中药股份有限公司 第八届监事会第十次会议决议公告 特别提示 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司第八届监事会第十次会议于 2024 年 10 月 15 日以电话、 邮件及其他网络通讯方式发出通知，于 2024 年 10 月 25 日以通讯方式召开。会议应出 席监事 3 名，亲自出席监事 3 名，符合《公司法》及《公司章程》的有关规定。会议由 监事会主席张华中主持，经认真审议，以"同意 3 票，反对 0 票，弃权 0 票"的表决结 果全票通过了《公司 2024 年第三季度报告》。 监事会对《公司 2024 年第三季度报告》进行了审慎审核，认为： 1、公司 2024 年第三季度报告的编制和审议程序符合法律法规、公司章程和公司内 部管理制度的规定。 2、公司 2 ...